**Core Concept**
Malignant hyperthermia (MH) is a rare but life-threatening medical emergency triggered by certain anesthetic agents, particularly volatile anesthetics and succinylcholine. It is characterized by an uncontrolled rise in body temperature, metabolic acidosis, and muscle rigidity.

**Why the Correct Answer is Right**
Malignant hyperthermia occurs due to an abnormal response of skeletal muscle to these anesthetic agents. The condition is caused by mutations in genes encoding the ryanodine receptor (RyR1) or the dihydropyridine receptor (DHPR), which are located on the sarcoplasmic reticulum and the T-tubules of skeletal muscle cells, respectively. These mutations lead to an uncoupling of the Ca2+ channels, resulting in an excessive release of calcium ions from the sarcoplasmic reticulum. This calcium overload triggers a series of biochemical reactions, including the activation of phosphocreatine kinase and the production of heat, leading to the characteristic symptoms of MH.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because malignant hyperthermia is not caused by a deficiency of the enzyme involved in the breakdown of succinylcholine.
**Option B:** This option is incorrect because malignant hyperthermia is not a condition characterized by a decrease in muscle tone; rather, it is associated with muscle rigidity.
**Option C:** This option is incorrect because malignant hyperthermia is not a condition caused by an allergic reaction to an anesthetic agent.

**Clinical Pearl / High-Yield Fact**
Malignant hyperthermia can be effectively treated with dantrolene, a skeletal muscle relaxant that inhibits calcium release from the sarcoplasmic reticulum. Early recognition and treatment of MH are crucial to prevent serious complications and death.

**Correct Answer:** D.